Search or
𝛼SK
𝛼SKbullish
Pre-IPO Softcare (PHIP Updates) - Some Points Worth the Attention
516 Views03 Nov 2025 08:55
Softcare's success lies in global supply chain expansion/low-price strategy, but growth may slow growth due to competition/lack of R&D. 8-12x P/E is reasonable due to high growth/risk in Africa.
What is covered in the Full Insight:
- Introduction: Rise of Softcare
- Business Model and Strategy
- Financial Performance and Projections
- Competitive Landscape
- Valuation and Investment Considerations
Boomeranged on Thu, 6 Nov 2025 16:40
Based on IPO pricing of HK$24.2-26.2, valuation is 20x PE based 2024 net profit and 21-23x PE based on 2025 forecast (US$90 million net profit), higher than Hengan International (13x PE) and valuation level in insight (8-12x PE).The IPO pricing is not cheap.The risk is growth slowdown/lack of technological barrier.Future valuation depends on whether Softcare can fulfill its high growth expectation
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (Nov.16) - Crazy Healthcare IPOs, Don't Bet on BD, Biokin HK IPO Delayed16 Nov 2025
- China Healthcare Weekly (Nov.9)-Medical Insurance “Warning Lines”, NewCo Model, BeiGene 25Q3 Results09 Nov 2025
- Pre-IPO Sichuan Biokin Pharmaceutical (PHIP Updates) - Some Points Worth the Attention27 Oct 2025
- Pre-IPO Tong Ren Tang Healthcare Investment (PHIP Updates) - Some Points Worth the Attention07 Oct 2025
- Pre-IPO Softcare - Strong Performance Growth Momentum Would Continue02 Jun 2025
x